富维斯特朗
帕博西利布
医学
危险系数
内科学
肿瘤科
安慰剂
乳腺癌
转移性乳腺癌
芳香化酶抑制剂
癌症
妇科
置信区间
雌激素受体
三苯氧胺
病理
替代医学
作者
Nicholas C. Turner,Dennis J. Slamon,Jungsil Ro,Igor Bondarenko,Seock‐Ah Im,Norikazu Masuda,Marco Colleoni,Angela DeMichele,Sherene Loi,Sunil Verma,Hiroji Iwata,Nadia Harbeck,Sibylle Loibl,Fabrice André,Kathy Puyana Theall,Xin Huang,C. Giorgetti,Cynthia Huang Bartlett,Massimo Cristofanilli
标识
DOI：10.1056/nejmoa1810527
摘要
Among patients with hormone-receptor-positive, HER2-negative advanced breast cancer who had sensitivity to previous endocrine therapy, treatment with palbociclib-fulvestrant resulted in longer overall survival than treatment with placebo-fulvestrant. The differences in overall survival in the entire trial group were not significant. (Funded by Pfizer; PALOMA-3 ClinicalTrials.gov number, NCT01942135 .).
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
无极微光
蓝天
OsamaKareem
memory
邓佳鑫Alan
wulanshu
嘉心糖
殷勤的紫槐
XQQDD
GingerF
didiwang
贪玩的秋柔
周不是舟
小乔
iNk
lizishu
科研狗
Moonpie
lalala
sanvva
皖公网安备34019202002308
